Pfizer Completes SpringWorks Therapeutics Acquisition
| Field | Detail |
|---|---|
| Company | Springworks Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, completed-deal
TL;DR
Pfizer just bought SpringWorks, closing the deal on June 13, 2025.
AI Summary
On June 13, 2025, SpringWorks Therapeutics, Inc. announced the closing of its acquisition by Pfizer Inc. The transaction was previously announced on March 20, 2024. This marks the end of SpringWorks' journey as an independent public company.
Why It Matters
This acquisition integrates SpringWorks' pipeline, particularly its promising therapies for rare diseases, into Pfizer's broader portfolio, potentially accelerating drug development and patient access.
Risk Assessment
Risk Level: low — The filing is a confirmation of a completed acquisition, which is a known event with a defined outcome.
Key Players & Entities
- SpringWorks Therapeutics, Inc. (company) — Company filing the report and being acquired
- Pfizer Inc. (company) — Acquiring company
- June 13, 2025 (date) — Date of closing of the acquisition
- March 20, 2024 (date) — Date the acquisition was initially announced
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report the closing of the acquisition of SpringWorks Therapeutics, Inc. by Pfizer Inc.
When did the acquisition of SpringWorks Therapeutics, Inc. officially close?
The acquisition officially closed on June 13, 2025.
When was the acquisition of SpringWorks Therapeutics, Inc. by Pfizer Inc. initially announced?
The acquisition was initially announced on March 20, 2024.
What is the exact name of the registrant filing this report?
The exact name of the registrant is SpringWorks Therapeutics, Inc.
What is the state of incorporation for SpringWorks Therapeutics, Inc.?
SpringWorks Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding SpringWorks Therapeutics, Inc..